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Abstract  
 
 Previous studies have shown that in utero exposure to diethylstilbestrol (DES), a 
synthetic form of estrogen, increases the risk of developing various forms of cancer, including 
breast cancer, later in life.1 Bisphenol A (BPA) has been shown to act as a synthetic estrogen, 
and acts similarly to DES in rodents.2  Both compounds belong to a class of compounds known 
as endocrine disrupting compounds (EDCs), known to have hormonal activity.  In utero BPA 
exposure can also increase the risk of developing breast cancer in rodents.3 The exact mechanism 
by which BPA alters the morphology of the mammary gland to create this susceptibility, 
however, is unknown. Using immunohistochemistry, we have shown that BPA affects the 
expression of two key proteins, Ki67 and ERα, in the stroma, correlating to significant defects in 
the epithelium. These data suggest that BPA induced alterations in the stroma may affect the 
epithelial phenotype, specifically ductal branching.  
 One cell type of the stroma, fibroblasts, contribute to the production of the extracellular 
matrix (ECM), which provides structural support for the epithelial ducts.  These cells also 
communicate with the developing epithelium through secreted proteins. Therefore, fibroblasts 
are critical to both the structure and function of the mammary gland.  Alterations to fibroblasts 
have the potential to lead to changes that can disrupt normal development and cellular function 
in the mammary gland. We performed transcriptome analysis and identified the extracellular 
matrix to be significantly altered in the BPA exposed mammary glands, so collagen 
deposition was investigated. We demonstrate that BPA exposed fibroblasts have increased 
collagen in the mammary glands, a molecular phenotype shown to increase cancer risk. 
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Introduction  
 
 From the 1940s to the 1960s, pregnant women were prescribed diethylstilbestrol (DES), a 
synthetic estrogen used to reduce the risk of premature delivery or miscarriage.4 The female 
children of women who took DES during pregnancy have been found to have an increased risk 
of developing a myriad of reproductive tract abnormalities, including clear cell adenocarcinoma, 
endometriosis, and infertility.1,5 These women, termed “DES daughters”, have also been found to 
have a two-fold increased risk of developing breast cancer later in life.1 In rodent models, 
bisphenol A (BPA) has been shown to act as a synthetic estrogen, like DES.6 Both compounds 
belong to a class known as endocrine disrupting compounds (EDCs) which have hormonal 
activity.  It is commonly accepted that exposures to EDCs during the critical periods of 
embryonic and fetal development are more likely to cause harm than exposure that occurs during 
adulthood.7 
 BPA is a compound used to make most plastics and resins. It is classified as a high 
production volume chemical, with releases to the environment currently exceeding one million 
pounds per year.8 Humans can be exposed to BPA from canned food and plastic products like 
water bottles and baby bottles, among many other sources. A study conducted by the Center for 
Disease Control found that 93% of people over the age of six had a detectable level of BPA in 
their urine.9 Furthermore, it has been found in human amniotic fluid, demonstrating that in utero 
BPA exposure is a relevant health concern, and its effects merit further study.10 In DES 
daughters, there was a long latency period between in utero exposure to DES and the beginning 
of disease, which was not typically observed until after the age of forty. Therefore, the potential 
harmful effects from BPA associated with increased plastics usage in the 1980s and 1990s have 
not yet manifested in the population, provided that there is a long latency period between BPA 
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exposure and disease, as there is with DES exposure.11  Breast cancer is the second deadliest 
cancer in women, and one in eight women will develop breast cancer in her lifetime.12  It is of the 
utmost importance that we determine the impact of in utero BPA exposure on increasing breast 
cancer risk and the mechanism of its effects, so that we understand the risk that BPA poses to the 
population and are better equipped to manage cancer prevention efforts. 
 In utero BPA exposure has already been shown to increase the risk of developing breast 
cancer in rodents.3 In mice, exposure has been shown to inhibit development of the mammary 
gland early in life, then accelerate it later in life.13-16 The activation of the estrogen receptor (ER) 
may be implicated in these changes, however, the exact mechanism by which BPA alters the 
morphology of the developing mammary gland to create this susceptibility is unknown.  
 Mammary gland development begins on embryonic day (E) 10.5 when the milk line 
forms, and continues on E11.5 when the placode forms (Figure 1).17 The placode cells then 
invaginate into the mesenchyme to form the primordial epithelial bud.  The surrounding 
mesenchyme serves as the only estrogen receptor (ER) -expressing compartment of the 
embryonic gland.17-20 Once these developing epithelial buds sink beneath the epidermis starting 
at E13.5, they remain completely surrounded by the ER-positive mesenchyme until 
approximately E16.5.18 The bud then proliferates out of the mesenchyme through the fat pad and 
into primary rudimental branching.17 It is unknown whether mammary gland susceptibility to 
EDCs like BPA varies throughout the different stages of embryonic development. Notably, 
cancers of the reproductive tract in DES daughters were found to be associated specifically with 
first trimester exposure to DES, indicating that there may be a critical window for EDC exposure 
during embryological and fetal development. 1, 21, 22  
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One particular component of the stroma, the extracellular matrix, is known to be 
deregulated in tumors. In addition, alterations in the expression of certain extracellular matrix 
components have been shown to increase cancer susceptibility.23 For example, increased 
collagen deposition within the mammary gland is a phenotype that has been shown to increase 
cancer risk.24 BPA exposure has been shown to alter collagen expression within the mammary 
gland, however, it is unknown whether this relationship is still valid when BPA exposure occurs 
in utero.25 
 We hypothesize that different windows of in utero exposure to BPA lead to varying 
degrees of altered phenotypes within the mammary gland. Specifically, we believe that both 
morphological changes, such as changes in epithelial elongation, and molecular changes, such as 
differences in ER expression, will be observed. In addition, we hypothesize that collagen 
Figure 1- Murine fetal mammary gland development. Development of the mammary gland begins around 
E10.5, and continues when the placode forms on E11.5. The cells then invaginate into the mesenchyme to form 
the primordial epithelial bud.  The surrounding mesenchyme serves as the only estrogen receptor (ER) -
expressing compartment of the embryonic gland, and the cells remain completely surrounded by this 
mesenchyme until E16.5.  
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deposition will be altered in mammary glands exposed to BPA in utero, as previous studies have 
reported differences in collagen deposition when mammary glands are exposed to BPA.25 
 
Materials and Methods 
Fetal Exposure to BPA in the Varied Treatment Model 
 Animal experiments were performed in compliance with the protocol approved by The 
Ohio State University institutional animal care and use committee (protocol number 
2013A00000030). Pregnant CD-1 mice were fed a diet containing minimal levels of 
phytoestrogen (2019X Teklad Rodent Diets; Harlan Laboratories Inc., Indianapolis, IN). The 
mice received a daily intraperitoneal (IP) injection of BPA, with a dosage of 25 ug per kg of 
body weight, between embryonic days (E) 8.5 and 18.5, the beginning stages of mammary gland 
development. E0.5 was defined as the day that a vaginal plug was observed following mating. 
Vehicle oil was administered to a second cohort during the same time frame, as a control. A 
variety of different treatment schemes were used during the E8.5-18.5 period, corresponding to 
embryonic developmental milestones. Mice were treated according to the following treatment 
schemes: E8.5 to E12.5 (BPA 1), E8.5 to E16.5 (BPA 2), E15.5 to E18.5 (BPA 3), and E8.5 to 
E18.5 (BPA 4). Mice treated with vehicle oil as the control received IP injections from E8.5 to 
E18.5 (OIL).  
 Female pups were separated from males, and then euthanized at 4.5, 14, and 20 weeks of 
age.  Mice from the same litter were divided among different time points to prevent littermates 
from being used for the same analysis. All mice at least 8 weeks of age were sacrificed during 
the estrus stage of the estrous cycle, which was initially identified using vaginal cytology, and 
later confirmed by hematoxylin and eosin analysis of the uterus, ovaries, and vagina. The fourth 
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inguinal mammary glands were harvested from each mouse. One mammary gland from each 
mouse was whole mounted and stained with carmine-aluminum.  The other gland was embedded 
in paraffin, sectioned, and used for immunohistochemical analysis. 
 
Mammary Whole Mount and Immunohistochemical Analysis 
 Carmine-aluminum stained mammary whole mounts were used for morphological 
analysis.  Digital images of whole mounts were obtained using a dissection microscope (Zeiss 
Stemi SV11 Apt stereomicroscope) at 0.6X magnification, equipped with a camera (AxioCam 
506 color) and Zeiss ZEN software. For early-life mammary glands (4.5 weeks of age), epithelial 
elongation was measured in millimeters plus or minus the distance from a line on the leading 
edge of the lymph node to the furthest point of epithelial branching. The number of terminal duct 
ends (TDEs) and the number of terminal end buds (TEBs) were also counted.  A width of 
0.15mm was used as a threshold for determining qualification for TEBs. The percentage of 
epithelial area was quantified using color thresholding and selection of epithelial branching in 
ImageJ.26 The percentage was used to normalize the number of TEBs counted for each treatment 
and was represented as a ratio.  All measurements were confirmed through blind analysis (n ≥7).  
 Carmine-aluminum stained whole mounts of mature (14 and 20 weeks of age) mammary 
glands were also analyzed by determining the percentage of epithelial area using color 
thresholding and selection in ImageJ.26 Digital images were obtained using a dissection 
microscope as described above. Images were captured with one field of view from each 
biological replicate (age 14 weeks, n ≥ 9; age 20 weeks, n ≥ 3) selected from the leading edge of 
the mammary gland, in front of the lymph node.  
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 Immunohistochemistry (IHC) was used to analyze both early-life and mature mammary 
glands.  Sections were stained using a Bond Rx autostainer (Leica Biosystems, Buffalo Grove, 
IL) and automated software (Bond Rx, version 4.0) in order to run optimized protocols. The 
slides were baked at 65°C for 15 minutes, and then dewaxing, rehydration, antigen retrieval, 
blocking, primary antibody incubation, postprimary antibody incubation, detection [3,30 -
diaminobenzidine (DAB) or Bond Polymer Red Detection], and counterstaining using Bond 
reagents (Leica) were performed by automated software. Samples were then removed from the 
autostainer, dehydrated, mounted, and coverslipped. Antibodies for the following markers were 
diluted in antibody diluent (Leica): rabbit antibody a-smooth muscle actin (SMA; 1:5000; 
Abcam, Cambridge, UK), ERa (1:2000; E115; GeneTex, Irvine, CA), and Ki67 (1:200, Abcam); 
and rat antibody cytokeratin 8 (1:2000; TROMA-I-C; Developmental Studies Hybridoma Bank, 
University of Iowa).  
 Four field-of-view images were captured for each biological replicate at 20X 
magnification using the Vectra Automated Multispectral imaging system. TDEs and ducts were 
imaged for 4.5-week-old mice, while alveolar buds and ducts were imaged for 14-week-old 
mice.  Four images of each type of structure for each biological replicate were acquired. Tissue 
compartment segmentation and quantification of positivity were performed using InForm 
Advanced Image Analysis Software, version 2.0.2 (Perkin Elmer, Waltham, MA). The InForm 
Tissue Finder software was used to determine tissue compartment positivity. Positivity was 
determined by manually segmenting tissue compartments into the stroma and the epithelium 
using SMA- positive staining to designate the epithelial compartment, using object-based 
segmentation to identify positive cells, and scoring using 2-bin positivity to identify the 
component DAB signal as positive for the staining performed (ERɑ or Ki67). Scoring was also 
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used to determine a threshold to differentiate between DAB-positive and DAB-negative, or 
hematoxylin and eosin only, nuclei.  The threshold for positivity was determined separately for 
both the stroma and the epithelium, and these thresholds were used to score all images. Results 
are represented as the percentage of positivity normalized to the total area of mammary tissue 
determined using the Inform software.  
 
Transcriptional Profiling 
 In order to determine which genes may be altered by in utero BPA exposure, and which 
pathways these genes correspond to, transcriptional profiling was performed. RNA from 
fibroblasts, luminal epithelial cells, and basal epithelial cells was isolated from the mammary 
glands of 13-week-old mice treated in utero with either oil or BPA as previously described.27  
Libraries for Illumina next generation sequencing were generated and sequenced by the Ohio 
State Genomics Core. Following RNA-seq, differentially regulated genes were identified and 
subjected to Ingenuity Pathway Analysis to detect altered processes.  
 
Collagen Deposition Analysis  
 Pregnant CD-1 mice were cared for as described above, and received a daily 
intraperitoneal (IP) injection of BPA or vehicle oil, with a dosage of 25 ug per kg of body 
weight, between E8.5 and 18.5.  Female pups were separated from males, and then euthanized at 
14 weeks. Mammary glands were harvested, fixed, paraffin-embedded, sectioned, and stained 
with Picrosirius red (PSR) in order to visualize the collagen within the gland. The slides were 
baked at 65°C for 10 minutes, deparaffinized, and soaked in a 1:2 dilution of hematoxylin and 
eosin in PBS for 3 minutes.  The slides were then rinsed in deionized water, washed with 
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ammonia water for one minute, and again rinsed with deionized water. Sirius red (abcam 
150681) was added to the tissue, and the tissue was incubated for one hour. The slides were 
washed twice in acetic acid solution (abcam 150681), dehydrated, and coverslipped. Two field of 
view images per biological replicate (n ≥ 11) were taken, one selected from the leading edge of 
the gland, and one selected from opposite the leading edge of the gland. Images were taken at 4X 
magnification using a Nikon Eclipse 50i microscope equipped with an Axiocam506 color Zeiss 
camera and Zeiss Zen Pro software, then cropped to a uniform size and randomized prior to 
analysis in ImageJ, so as to blind the analysis. The lymph node was removed and the image was 
color thresholded to determine the total area of the tissue.  The image was then again color 
thresholded to determine the area of epithelial branching. The total area of PSR staining and the  
intensity of the PSR staining for each digital image was quantified in ImageJ.26 
 
Results  
BPA exposure during different in utero windows results in varying phenotypes of the early-life 
mammary gland 
 
 In order to assess the effect of in utero BPA exposure during different stages of 
embryological development, four different dosing schemes were used that correspond to 
milestones in the embryological development of the mammary gland (Figure 2A). We examined 
BPA exposure during the period of milk line formation but before bud invagination into the ER-
expressing mesenchyme (BPA1, E8.5 to E12.5), the period from milk line formation through bud 
invagination into the mesenchyme (BPA2, E8.5 to E16.5), the period during which the 
epithelium begins to extend toward the fat pad until it has begun branching (BPA3, E15.5 to 
E18.5), and the duration of exposure that resulted in previously reported phenotypes (BPA4, 
E8.5 to E18.5).17-20  
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 By examining carmine-aluminum stained mammary glands from 4.5-week-old mice, we 
found that the window of in utero BPA exposure affected the delayed epithelial growth 
phenotype that has been previously reported. Specifically, in mice treated with BPA after E12.5, 
there was a clear defect in epithelial elongation from the leading end of the mammary gland 
lymph node (Figure 2B, dashed line) to the most distal epithelial branching (Figure 2B, solid 
line).  There was no significant difference between the epithelial elongation in mice treated 
before E12.5 (BPA1) and the epithelial elongation in control mice.  Epithelial elongation for 
BPA2 (P < 0.001) and BPA3 (P < 0.05), however, was significantly less than that of the control 
group and similar to that of mice who were treated with BPA throughout the entirety of fetal 
mammary gland development (BPA4, P < 0.001; Figure 2B; n ≥ 7). In early-life glands, only 
Figure 2 – BPA exposure alters the epithelial development in 4.5-week-old mammary glands.
65
 (A) Dosing 
schemes for in utero BPA treatments with 25 µg/ kg• bw/ day BPA, beginning embryonic day (E) 8.5 and varied 
through 18.5. BPA1: E8.5-12.5; BPA2: E8.5-16.5; BPA3: E15.5-18.5; and BPA4: E8.5-18.5. (B) Carmine-
aluminum stained whole mount mammary glands were used to measure epithelial elongation from the leading edge 
of the lymph node (dashed line) to the most distal portion of the epithelial tree (solid line). Graph represents 
comparison of epithelial elongation in millimeters, between treatments, and each dot represents separate biological 
replicates, n ≥ 7. (C) The number of terminal end buds (TEBs, indicated by arrowheads) were counted for each 
mammary gland. Graph represents comparison of number of TEBs between treatments, each dot representing 
separate biological replicates, n ≥ 7. Orange dots indicate the data point used for representative images (B) and (C). 
* = p < 0.05, ** = p < 0.001.  
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mice who received the BPA4 treatment exhibited a statistically significant reduction (P < 0.005) 
in the number of TDEs (Figure 2C and 2D). While BPA2 and BPA3 did demonstrate decreased 
numbers of TDEs, this difference was not statistically significant. In addition, recapitulation of 
the phenotypes observed in previous studies demonstrated an increase in the ratio of TEBs 
(Figure 2C and 2E) to the total epithelial area in the treatment periods after E12.5 (Figure 2D).  
Differences at BPA4 reached statistical significance (P < 0.005), while the differences at BPA2 
and BPA3 demonstrated a phenotypic trend, but were not statistically significant. 
 ERɑ expression and proliferation (Ki67) were examined in both the epithelium and the 
stroma surrounding TDEs and TEBS in 4.5-week-old mice using sections from inguinal 
mammary gland tissue.  To distinguish the epithelial tissue from the surrounding stroma, IHC of 
SMA was used. The positivity of Ki67 and ERɑ was determined within both the epithelium and 
the stroma for each treatment scheme (Figure 3A and 3B, n ≥ 7).  Within the stroma, ERɑ 
positivity was significantly increased with BPA 2 (P < 0.05), BPA3 (P < 0.05), and BPA4 (P < 
0.001) when compared to controls, while there was no significant difference with BPA1. Ki67 
expression, in contrast, was significantly decreased in the stroma surrounding TDEs and TDEs 
with BPA2 treatment (P < 0.001). BPA3 and BPA4 treatments also exhibited a trend in 
decreased Ki67 positivity, although this trend was not statistically significant (Figure 3B). There 
were no notable changes in ductal Ki67 positivity in either tissue compartment, across all 
treatments. Within the epithelium, only BPA4 treatment resulted in significant changes in Ki67 
and ERɑ expression.  
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 Molecular changes in the stroma (Figure 3C) were found to correlate with early-life 
dysfunction of epithelial elongation (Figure 2B). When comparing all mammary glands, 
regardless of the in utero exposure window, it was noted that epithelial elongation was correlated 
significantly and inversely with ERɑ positivity (Figure 3C, left graph; R = 20.54, P < 0.0001) 
and directly with Ki67 positivity (Figure 3C, right graph; R = 0.44, P < 0.001) within the stroma, 
even when the BPA4 treatment scheme was excluded. In addition, epithelial elongation 
significantly correlated with epithelial ERɑ positivity (Figure 3D, left graph; R = 20.32; P < 
0.05) and Ki67 positivity (Figure 3D, right graph; R = 0.43; P < 0.05).  However, this 
relationship was only present when BPA4 was included in the analysis.  
Figure 3 – Early life epithelial dysfunction of the mammary gland by in utero BPA significantly correlates to 
molecular changes to the stroma.
65
 Mammary glands from 4.5-week-old mice were dual-stained with smooth 
muscle actin (SMA, pink) and (A) ERα (brown) or (B) Ki67 (brown) (20x magnification); Inset depicts the tissue 
segmentation of the oil sample by InForm Advanced Image Analysis Software, differentiating the stroma (red) and 
epithelium (green). Graphs present (A) ERα or (B) Ki67 positivity (%) in the stroma (left), and epithelium (right). 
Each dot represents separate biological replicates, n ≥ 7 . Orange symbols indicate the representative images shown 
for each treatment. Epithelial elongation (Figure 2B) was correlated to the stromal ERα and Ki67 positivity from 
matched mammary glands across all treatments. Significant correlations were observed between (C) ERa (R2 = -
0.54) and (D) Ki67 positivity (right, R2 = 0.44). * = p < 0.05, ** = p < 0.001, **** = p < 0.0001. Dotted lines 
indicate 95% confidence interval. 
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BPA exposure during different in utero windows changes ERɑ expression in the adult mammary 
gland 
 
 We evaluated both morphological and molecular changes in 14-week-old mice to assess 
whether early-life defects in the mammary gland translated to later-life development. Dual 
stained tissue segments revealed that ERɑ positivity varied between each treatment scheme, most 
substantially for the epithelial–alveolar structures and surrounding stroma (Figure 4, n ≥ 4). 
Similarly to 4.5-week-old mice, 14-week-old mice that received BPA1 treatment exhibited no 
difference in ERɑ positivity in either the stroma or the epithelium when compared to control 
mice.  BPA3 treated mice also showed no changes in either tissue compartment when compared 
with controls. In BPA4 mice, however, ERɑ positivity was significantly decreased in both the 
stroma and the epithelium (P < 0.05). BPA2 treatment also resulted in a significant decrease in 
epithelial ERɑ positivity and a significant difference in stromal ERɑ positivity (Figure 4). Ki67 
positivity was not altered when compared to controls for any treatment, in either tissue 
compartment (data not shown). 
 
Figure 4 – ERα expression is altered in the adult mammary gland by in utero BPA exposures.
65
 
Representative images are shown of in utero-treated mammary glands from 14-week-old mice dual-stained with 
SMA and ERα, focused around alveolar structures (20X magnification). The inset depicts the tissue segmentation 
of the stroma (red) and epithelium (green) in the representative oil-treated gland. Graphs display ERα positivity 
(%) quantified in the alveolar structures of the epithelium (left) and the surrounding stroma (right). Each dot 
represents separate biological replicates, n ≥ 12, and orange symbols indicate the representative images shown for 
each treatment. * = p < 0.05, ** = p < 0.001. 
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In utero BPA exposure changes the morphology of ducts to varying degrees based on the window 
of exposure 
 
 Carmine-aluminum stained mammary whole mounts of adult 14- week-old (Figure 5A, n 
≥ 9) and 20-week-old (Figure 5B, n ≥ 3) mice were examined in order to assess the ability of our 
model to replicate previous observations that in utero BPA exposure increases the epithelial 
volume and changes ductal morphology. BPA2 and BPA4 mice both exhibited statistically 
significant increases in epithelial area (Figure 5A, P < 0.05), mirroring trends in ERɑ expression 
in 14-week-old mice, but no changes were observed in BPA1 and BPA3 treated mice. These 
phenotypes were consistent through 20 weeks (Figure 5B, P < 0.05). While BPA1 and BPA3 
treatment showed a trend toward increased epithelial area at 20 weeks, this difference was not 
statistically significant (P = 0.051 and P = 0.082, respectively). These data suggest that in utero 
BPA exposure driven alterations that occur during early-life can be propagated into adulthood 
when exposure occurs after E12.5.  
 
Figure 5 - In utero BPA exposure significantly alters the density and complexity of the epithelium of the 
mammary gland.
65
 Color thresholding was performed in ImageJ to quantify epithelial area in carmine-stained 
mammary whole mounts. Representative dissection light microscope images are shown from (A) 14-week-old 
and (B) 20-week-old adult mice. Graphs represent the area of epithelium as measured by pixels in epithelium out 
of total pixels in field of view (%). Each dot represents separate biological replicates, (A) n ≥ 9 and (B) n ≥ 3 and 
orange symbols indicate the representative mammary gland shown. * = p < 0.05. 
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In utero BPA exposure alters the extracellular matrix, specifically collagen deposition  
 
 Transcriptional profiling was performed using RNA isolated from fibroblasts, luminal 
epithelial cells, and basal epithelial cells from 13-week-old mice treated in utero with either oil 
or BPA. It was noted that genes associated with the extracellular matrix were found to be 
significantly altered in mice that were exposed in utero to BPA (Table 1).  
 Since collagen is a significant component of the extracellular matrix, it was selected for 
further analysis. Using PSR staining and subsequent analysis in ImageJ, it was determined that in 
14-week-old mammary glands that were exposed to in utero BPA, both the average area of PSR 
staining (P < 0.005) and the average intensity of PSR staining (P < 0.005) were both significantly 
different from control glands (Figure 6).  This indicates that in utero BPA exposure alters 
collagen deposition in adult mammary glands. 
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Discussion 
Susceptibility to in utero BPA varies throughout fetal development  
 Exposure to EDCs during the critical periods of embryonic and fetal development can 
effect harmful changes in hormone-dependent organ development that can increase the risk of 
developing cancer.7 Exposure during the first trimester was shown to be the most detrimental for 
DES daughters, who were found to have the greatest risk of developing vaginal cancer when 
exposure occurred this period.1, 28, 29 To our knowledge, however, no study has been performed 
to establish a similar window of susceptibility for breast cancer development. While in utero 
BPA exposure has been shown to increase both the number of TEBs and cancer risk in rodents, 
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the mechanism by which BPA causes these defects and creates this susceptibility that extends to 
adulthood is not well understood.30-32 Therefore, we selected four windows of mammary gland 
development within which we could test the effects of BPA exposure. We observed that defects 
within the mammary gland were present when BPA treatment occurred after E12.5, after the 
epithelial bud had invaginated into the ERɑ-expressing mesenchyme. BPA1, treatment from 
E8.5 to E12.5, showed no evidence of mammary gland defects. BPA2 and BPA4 (schemes that 
included treatment from E12.5 to E18.5) exhibited significant defects, consistent with previous 
reports. At 4.5 weeks of age, BPA exposure resulted in decreased epithelial elongation, a 
decreased number of TDEs, and an increase in the ratio of TEBs to the total area of the 
epithelium  (Figure 2B and 2C). BPA1, BPA2, and BPA3 all demonstrated an increase in Ki67 
positivity, while BPA4 treatment resulted in a significant decrease in Ki67 positivity when 
compared with controls. Most of the significant early and later-life phenotypes were observed 
when the window of exposure included E12.5 to E16.5 (BPA2 to BPA4).  
 A potential caveat of our treatment model was that BPA2 and BPA4, the windows which 
resulted in the most significantly altered phenotypes, were treated for longer periods of in utero 
development (8 and 10 days versus 4 and 3 days for BPA1 and BPA3, respectively). Despite 
this, it is important to note that BPA3, while only treated for 3 embryonic days, resulted in a 
phenotype that was substantial, but diminished, when compared to controls. In addition, the 
BPA1 dosing scheme, spanning 4 days, did not result in noticeable defects to the mammary 
gland, indicating that the total duration of BPA exposure is not the driving factor for the 
observed changes. It is important to note that due to the rate of clearance of BPA in mice, 
exposure persists after the defined treatment windows, and therefore, the true exposure period 
cannot be identified in its entirety.33 However, the different dosing schemes used did produce 
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differing mammary gland phenotypes, and exposure that occurred before E12.5 generally did not 
produce substantial defects.  
The Role of  ERɑ in mammary gland changes caused by in utero BPA exposure  
 BPA exposure has been thought to cause deregulated mammary development and later-
life defects through its ability to interaction with the ERs.34-39 ERɑ activation within the stroma 
has been suggested to be the driver of BPA-induced alterations within the mammary gland.16,19,40 
Notably, BPA-induced changes in murine mammary glands were found to be blocked when mice 
were treated with the estrogen antagonist fulvestrant, indicating that BPA may act through ERs 
in the stroma.41 Taken together with our findings, this suggests that the stroma plays a key role in 
the development of the mammary epithelium, as previously reported.42-45 In addition, it also 
suggests that the stroma is involved in effecting later-life mammary defects. It is possible that the 
BPA-altered mesenchyme can reprogram the epithelium through paracrine signaling after 
inappropriate ERɑ activation. It follows that this signaling would result in the most significantly 
altered phenotype when the developing mammary gland is completely surrounded by the ERɑ -
positive mesenchyme, which occurs between E12.5 and E16.5.18 This window is represented by 
dosing schemes BPA2 and BPA4, which were found to have the most significantly altered 
phenotypes.  
 It has been shown previously that in mice, only 4% of stromal cells are weakly ERɑ- 
positive in immediate postnatal development; ERɑ expression continue to increase in both the 
number of positive cells as well as in intensity throughout adolescence and adulthood.46 This 
finding was recapitulated by examining the ERɑ positivity within the 4.5-week-old control 
mammary glands. BPA was found to increase the number of ERɑ-expressing cells in TDEs in 
4.5-week-old mice, as demonstrated in BPA4 mice, and in both BPA2 (P  < 0.05) and BPA4 (P < 
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0.05), ERɑ expression was significantly reduced in the epithelium. Until recently, the importance 
of ERɑ signaling within the stroma of the mammary gland during development has not been well 
understood. Recently, it was shown that BPA also interferes with mammary gland development 
even in an ex vivo model which eliminates any effects that BPA could elicit in the hypothalamic–
pituitary– gonadal axis, supporting the conclusion that BPA acts upon the ERɑ-positive stroma 
to alter mammary gland development.47 
 While BPA has been shown to interact with other hormone receptors, such as ERβ, 
studies investigating knockout models of these receptors make it clear that ERɑ is primarily 
responsible for later-life development of the mammary gland.35, 37, 48-52 In addition, BPA2 mice, 
who exhibited the most highly altered phenotype, were not exposed to BPA during the period in 
which ERβ is expressed (E18). Therefore, our model suggests that in utero, BPA acts on ER-
expressing mesenchymal cells to alter signaling within the mammary gland and cause 
phenotypical changes. Our model also indicates that ERɑ activation is crucial for these BPA-
induced alterations.  
 We acknowledge that there may be differences in mammary gland in utero ERɑ 
expression between humans and mice. For example, humans express ERɑ beginning after week 
30 of gestation, while mice do not express ERɑ in the epithelium until after birth. In addition, no 
study has ever demonstrated in utero ERɑ expression in the mesenchyme in humans. 
Furthermore, the period during which we found the developing mammary gland most susceptible 
to BPA-induced defects (E12.5 to E16.5) corresponds to weeks 7 though 14 of human gestation, 
but no study has investigated ERɑ expression before week twelve, and only a few have done so 
before week 18.53-55 Weeks 7 through 14 correspond to the end of the first trimester of human 
gestation;46 this is also when the highest rates of vaginal misdifferentiation effects were noted.1,56 
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No study has yet correlated breast cancer susceptibility to the window of exposure, but one study 
has correlated vaginal defects to breast cancer susceptibility.1,22 Together, these data suggest that 
human susceptibility to breast cancer occurs before ERɑ begins to be expressed in the epithelium 
in the third trimester.  
Influence of stromal signaling on mammary gland defects 
 The importance of stromal-epithelial interactions within the mammary gland has long 
been known to play an important role in mammary gland development, and our in utero BPA 
exposure model provides further support for this relationship.42-44, 57 Even when ER is not 
expressed, estrogenic compounds can still act directly on mammary tissue to alter the 
development of the epithelium.41 In addition, disruption of the communication that occurs 
between the stroma and the epithelium can result in tumorigenesis.44, 57-62 Therefore, determining 
the effects of BPA exposure on this process is necessary to elucidating the mechanism through 
which BPA creates cancer susceptibility. A significantly higher number of ERɑ-positive stromal 
cells surround the TDEs in early-life mammary glands exposed in utero to BPA (Figure 3A). 
This observation could suggest that these mammary glands are undergoing puberty prematurely, 
since the number of ERɑ-positive stromal cells has been shown to increase during puberty.46,63 In 
addition, it has been previously demonstrated that stromal ERɑ staining is confined to only 
undifferentiated mesenchymal cells, rather than to adipocytes or fibroblasts.63 This suggests that 
in utero BPA exposure can cause an increase in undifferentiated mesenchymal cells, which can 
promote tumor growth and metastasis. It follows that BPA may stimulate the development of the 
epithelium indirectly through ERɑ-positive progenitors in the stroma.14, 16, 59, 64, 65 
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The effects of BPA on collagen deposition  
 Collagen accounts for a significant component of the extracellular matrix and is 
important for maintaining the structure of tissue. Using PSR staining, we demonstrate that in 
utero BPA exposure results in an increase in the amount of collagen within the mammary gland. 
It is known that increased collagen within the mammary gland, causing denser breast tissue, is 
correlated with an increased risk of breast cancer. The tumor microenvironment, which includes 
the extracellular matrix, is involved in tumor progression, and tumors are often characterized by 
the remodeling and stiffening of the extracellular matrix.23 Furthermore, increased collagen 
expression and deposition have previously been shown to be implicated in tumor progression, 
especially in mammary tumors.24 Therefore, the increase in mammary gland collagen deposition 
that we found to be caused by in utero BPA exposure is significant because this is a phenotype 
that has been shown to increase cancer risk.  
 
Conclusion 
 Despite the absence of ERɑ positivity within the epithelium of BPA-exposed mammary 
glands, significant epithelial effects were observed following our treatment model. These 
alterations in the morphology of the mammary gland were noted when in utero exposure 
occurred between E12.5 and E16.5 (BPA2 and BPA4 treatment windows). This demonstrates 
that the timing of in utero exposure can influence cancer risk later in life.  Similar changes were 
noted in women exposed to DES in utero, who were found to have a twofold increased risk of 
developing breast cancer after the age of 40.1, 21, 22 Notably, women with vaginal epithelium 
changes found to be associated with first trimester DES exposure had a higher risk of breast 
cancer.1, 22 In humans, the mammary bud begins to invade the parenchyma during week of eight 
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of gestation, during the first trimester, and this corresponds to E12.5 in the gestation of mice.46 
The period of development beginning at E12.5 was observed to be when the mammary gland 
was most susceptible to BPA-induced defects; these defects were observed in both early and later 
life mice. This data suggests that ERɑ may play a role in mediating BPA-induced alterations in 
the mammary gland.  
 We also demonstrate that in utero BPA exposure causes increased collagen deposition in 
the mammary gland, a molecular phenotype shown to increase cancer risk, indicating that BPA 
exposure alters the extracellular matrix, a crucial component of the mammary gland.24  It is 
commonly accepted that high breast density is correlated with an increased incidence of breast 
cancer. Together, our data demonstrate the need to further characterize the role of ERɑ in in 
utero BPA caused mammary gland defects and to further investigate potential defects in the 
extracellular matrix.  
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